Is Rising Sales and a Swing to Net Loss Changing the Investment Case for LivaNova (LIVN)?

Simply Wall St.

Nov 06, 2025

LivaNova PLC reported its third quarter and nine-month 2025 earnings, showing sales growth to US$357.8 million for the quarter and US$1.03 billion for the nine months, compared to the same periods ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581887480"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581887480\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581887480?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-11-06 03:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581887480","market":"hk","top_or_hot":-1,"title":"Is Rising Sales and a Swing to Net Loss Changing the Investment Case for LivaNova (LIVN)?","media":"Simply Wall St.","content":"<div>\n<p>LivaNova PLC reported its third quarter and nine-month 2025 earnings, showing sales growth to US$357.8 million for the quarter and US$1.03 billion for the nine months, compared to the same periods ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/is-rising-sales-and-a-swing-to-net-loss-changing-the-investm\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Rising Sales and a Swing to Net Loss Changing the Investment Case for LivaNova (LIVN)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Rising Sales and a Swing to Net Loss Changing the Investment Case for LivaNova (LIVN)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-06 03:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/is-rising-sales-and-a-swing-to-net-loss-changing-the-investm><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LivaNova PLC reported its third quarter and nine-month 2025 earnings, showing sales growth to US$357.8 million for the quarter and US$1.03 billion for the nine months, compared to the same periods ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/is-rising-sales-and-a-swing-to-net-loss-changing-the-investm\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIVN","symbol_name":"LivaNova PLC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/is-rising-sales-and-a-swing-to-net-loss-changing-the-investm","article_id":"2581887480","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/is-rising-sales-and-a-swing-to-net-loss-changing-the-investm","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581887480","pubTimestamp":1762372501,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"LivaNova PLC reported its third quarter and nine-month 2025 earnings, showing sales growth to US$357.8 million for the quarter and US$1.03 billion for the nine months, compared to the same periods last year.\nWhile sales increased, the company saw quarterly net income decline and posted a net loss of US$273.4 million for the nine-month period, shifting from net income last year.\nWe'll explore how the combination of higher sales and a substantial nine-month net loss reshapes LivaNova's...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LIVN":"LivaNova PLC"},"translate_title":"销售额的增长和净亏损是否正在改变LivaNova(LIVN)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":1.5},"content_text":"LivaNova PLC reported its third quarter and nine-month 2025 earnings, showing sales growth to US$357.8 million for the quarter and US$1.03 billion for the nine months, compared to the same periods last year. While sales increased, the company saw quarterly net income decline and posted a net loss of US$273.4 million for the nine-month period, shifting from net income last year. We'll explore how the combination of higher sales and a substantial nine-month net loss reshapes LivaNova's investment outlook. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementLivaNova Investment Narrative RecapTo be a shareholder in LivaNova, you need to believe in its ability to grow sales through clinical innovation in neuromodulation and cardiopulmonary technologies, even as the company works to restore profitability. The recent report of higher nine-month sales but a sharp net loss puts the spotlight on margin pressures; while the revenue climb supports hopes for future procedure growth, the biggest short-term risk remains whether cost and reimbursement challenges could continue to weigh on earnings, a factor not materially amplified by this quarter’s results. One of the most relevant developments is the August 18th commercial launch of the Essenz Perfusion System in China, a move designed to expand LivaNova’s global reach and capitalize on rising procedure volumes abroad. This expansion ties directly into the most important near-term catalyst: international adoption of advanced devices supporting recurring revenue and longer-term market share gains. However, in contrast to expansion plans, the company’s exposure to global reimbursement scrutiny remains a detail investors should watch closely… Read the full narrative on LivaNova (it's free!)LivaNova's outlook anticipates $1.6 billion in revenue and $168.9 million in earnings by 2028. This scenario is predicated on a 6.4% annual revenue growth rate and a $380 million increase in earnings from the current $-211.3 million.Uncover how LivaNova's forecasts yield a $65.00 fair value, a 21% upside to its current price.Exploring Other PerspectivesLIVN Community Fair Values as at Nov 2025 Simply Wall St Community members have produced fair value estimates for LivaNova ranging from US$65 to US$181, reflecting two different viewpoints. While multiple participants see upside potential, remember that ongoing global cost and margin risks could shape the company’s future return profile, explore these contrasting forecasts for a fuller picture.Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $65.00!Build Your Own LivaNova NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your LivaNova research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.Searching For A Fresh Perspective?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}